Can-Fite BioPharma Ltd.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-9.8M | $-7.9M | $-7.6M | $-10.2M | $-12.6M | $-14.4M | $-12.6M | $-6.6M |
| Depreciation & Amortization | $24.0K | $7.0K | $15.0K | $14.0K | $14.0K | $12.0K | $14.0K | $14.0K |
| Depreciation | $24.0K | $7.0K | $15.0K | $14.0K | $14.0K | — | $14.0K | $14.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $340.0K | $362.0K | $261.0K | $263.0K | $466.0K | $355.0K | — | — |
| Net Cash from Operating Activities | $-8.9M | $-7.6M | $-8.4M | $-10.8M | $-9.9M | $-12.1M | $-11.1M | $-4.2M |
| Investing Activities | ||||||||
| Capital Expenditures | $2.0K | $5.0K | $2.0K | $9.0K | $11.0K | $26.0K | $3.0K | $33.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-2.0K | $1.5M | $498.0K | $9.5M | $-14.5M | $-26.0K | $-3.0K | $-33.0K |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | $2.6M | $715.0K | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $9.6M | $6.7M | $9.1M | — | $20.5M | $17.7M | $10.2M | $4.4M |
| Net Change in Cash | $703.0K | $547.0K | $1.3M | $-1.4M | $-3.9M | $5.6M | $-918.0K | $110.0K |
| Free Cash Flow | $-9.0M | $-7.6M | $-8.4M | $-10.8M | $-9.9M | $-12.1M | $-11.1M | $-4.2M |